Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry
23 May 2022 (14:55 - 15:40)
Organised by:
Abstract
Slides
About the speaker
University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)
4 More presentations in this session
Doctor A. D'Amato (Rome, IT)
Impact of obstructive sleep apnea in patients undergoing left ventricular assist device implantation
Doctor N. Patel (Hartford, US)
Mr M. Garus (Wroclaw, PL)
Access the full session
The Event
Heart Failure 2022
23 May 2022
14:55 CET
You may be interested in
Congress Session
